Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity [Seeking Alpha]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Seeking Alpha
Verastem's Avutometinib and Defactinib combination therapy targets recurrent LGSOC and is expected to complete its rolling NDA by 2H2024. The company has a diverse pipeline, exploring treatments for metastatic pancreatic cancer and mKRAS G12C non-small cell lung cancer (NSCLC). Interim results for Avutometinib + Defactinib show a 45% ORR overall and 60% ORR for KRAS-mutant patients, with tumor regression in 86%. VSTM's cash balance post-capital raise is $144.5 million, providing a 1.3-year runway, enough to fund operations until the FDA's decision. The company's cash reserves and potential TAM in LGSOC justify a speculative "buy" rating at its low valuation despite its inherent biotech risks. KatarzynaBialasiewicz/iStock via Getty Images Verastem, Inc. ( NASDAQ: VSTM ) is a clinical-stage biopharmaceutical company that develops cancer treatments targeting the RAS/MAPK pathway. This cell growth modulator is useful for pancreatic, lung, colorectal, and low-grade serous ovar
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem, Inc. (NASDAQ: VSTM) had its price target raised by analysts at B. Riley from $7.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Verastem Oncology to Present at the Guggenheim SMID Cap Biotech ConferenceBusiness Wire
- Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at Guggenheim.MarketBeat
- Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven CancersBusiness Wire
- Verastem Oncology Names Matthew E. Ros as Chief Operating OfficerBusiness Wire
VSTM
Earnings
- 8/8/24 - Beat
VSTM
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- 2/14/25 - Form SCHEDULE
- VSTM's page on the SEC website